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onresponse is a frequent phenomenon in both
somatic and psychiatric pharmacotherapy.A consider-
able number of drugs have become available for the
treatment of various psychiatric diseases since the dis-
covery of chlorpromazine 50 years ago.
1 Despite all the
progress in this field,there are still many patients who
do not respond to treatment,so-called nonresponders.
Around 20% to 30% of the patients with schizophrenia
are thought to be nonresponders to one or more psy-
chotropic drugs.
Several reasons for nonresponse to treatment have been
considered.The main issue is the heterogeneity of schiz-
ophrenic disorders,which can result in different clinical
pictures.The existing theories discussed for schizophre-
nia (Figure 1) may be only a small part of the existing
mechanisms causing schizophrenia.Consequently,the
research strategy is to focus on the effects of alterations
N
Treatment-resistance in schizophrenia remains a public health problem: about 20% to 30% of patients do not respond
to antipsychotic therapy. Clozapine has been shown to be effective in about one-third of patients, but the medical
risks and weekly blood tests limit its broad application. While the heterogeneity of the disease and the duration of
untreated psychosis are important, pharmacogenomic aspects must also be considered. Pharmacogenomic investiga-
tions offer the opportunity to individualize antipsychotic therapy according to the growing knowledge of the func-
tion and effect of the genetic polymorphisms that affect the pharmacokinetics and pharmacodynamics of antipsy-
chotics. On the pharmacokinetic level, polymorphic phase I and II drug-metabolizing enzymes and transport proteins
affect drug concentration at the target structure. The cytochrome P450 enzymes, N-acetyltransferase, and multidrug
resistance protein (MDR1) particularly influence this parameter. Genetic alterations affecting drug pharmacodynamic
properties have an impact on therapeutic outcome that is generally independent of the applied dosage regimen. A
combined analysis of genetic polymorphisms in the dopaminergic and serotonergic receptors, neurotransmitter trans-
porters, and other target structures involved in psychiatric disorders is already a powerful predictor of therapeutic out-
come. An understanding of other factors influencing gene expression and protein production will facilitate individ-
ualized therapy in the future.  
© 2004, LLS SAS Dialogues Clin Neurosci. 2004;6:71-77.in drug target proteins. In addition, the duration of the
untreated psychosis seems to adversely affect acute treat-
ment response and short-term outcome.
2 Here, we will
focus on the pharmacokinetic and pharmacodynamic
aspects of nonresponse to treatment in schizophrenia.
The atypical antipsychotic clozapine,which was licensed
in the USA especially for the treatment of so-called treat-
ment-resistant schizophrenia
3 (after having been available
in Europe since 1968
4),is not effective in all patients and
20% to 30% are known to be nonresponders.In a natu-
ralistic study in the psychiatric clinic of the University of
Munich,responders with no relapse were compared with
responders with partial relapse.The response rate was only
partially dependent on dose and plasma levels.
• Responders received an average dosage of 225 mg/day
clozapine and had a plasma level of 205 ng/mL clozapine
on average and 120 ng/mL desmethylclozapine per day.
• Responders with partial relapse received lower dosages
(125 mg/day) and also had lower plasma levels (100
ng/mL clozapine,55 ng/mL desmethylclozapine,respec-
tively).
• Nonresponders received higher dosages (250 mg/day)
and generally also showed considerably higher plasma
levels (290 ng/mL clozapine and 225 ng/mL desmethyl-
clozapine,respectively).
Therefore the nonresponders did not respond to therapy
even though they received higher dosages and had higher
plasma levels (Messer T,personal communication).and
that additional factors are involved.
Pharmacogenomics
Pharmacogenomics is the study of how an individual’s
genetic inheritance affects the body’s response to drugs
(Figure 2).This includes both the interindividual side-
effect profile and the therapeutic outcome. Single
nucleotide polymorphisms (SNPs) occur every 100 to 300
bases in the human genome,leading to a large number of
possible associations with response to pharmacotherapy.
Keeping this in mind,current research activities mainly
focus on pharmacokinetic and pharmacodynamic alter-
ations.Most notably,genes coding for the metabolizing
and transport proteins and drug target structures (recep-
tors,transporters,and signal transduction pathways) are
being investigated.
Pharmacokinetics
Various reasons have been discussed for nonresponse
(Table I).Among these is the important role of pharma-
cokinetic and pharmacodynamic aspects.These are partly
based on functional genetic polymorphisms of the
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Selected abbreviations and acronyms
HPP
+ haloperidol pyridinium
MDR1 multidrug resistance protein
NAT N-acetyltransferase
P-gp P-glycoprotein
SNP single nucleotide polymorphism
Figure 1. Theories for schizophrenia. NMDA, N-methyl-D-aspartate.
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Figure 2. Pharmacogenomics: the study of how genetic inheritance
affects the body’s response to drugs.
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300responsible genes.Pharmacokinetics,ie,the distribution
and metabolism of drugs,is dependent on genetic vari-
ants of the metabolizing enzymes and transport proteins.
Some of these are:
• The P450 cytochromes,which are members of the phase
I metabolizing enzymes responsible for oxidation of
functional groups.
• The phase II metabolizing enzyme N-acetyltransferase
(NAT),which is responsible for the conjugation of sub-
stances with hydrophilic molecules for facilitated renal
excretion.
• The multidrug resistance protein (MDR1),which con-
trols the active transport through the membranes of cells.
These determine the plasma levels and also the spectrum
of metabolites,and are thus responsible for the effects
and side effects of drugs.In addition,psychotropic drugs
interact at this level and influence each other.
Cytochrome P450 enzymes
Various cytochromes are responsible for the metabolism
of psychotropic drugs,
5 most notably cytochromes
CYP2C19,CYP3A4,CYP1A2,and CYP2D6.Haloperidol,
for example, is metabolized by CYP2D6, CYP3A4, and
CYP1A2. Notably, the enzyme CYP2D6 exists in more
than 20 different genetic variants,so-called polymorphisms,
which show different enzymatic activities.
Next,there are slow metabolizers,extensive metaboliz-
ers,and ultrarapid metabolizers.Several allelic variants
of the CYP2D6 gene can lead to a nonfunctional enzyme
or reduced CYP2D6 activity.The most common muta-
tions in Caucasians associated with a slow metabolizer
phenotype are the CYP2D6*3*4*5*6 alleles,or combi-
nations of these,leading to a nonfunctional enzyme or
reduced activity when they occur as heterozygous com-
binations with the wild-type allele.The ultrarapid metab-
olizer CYP2D6 phenotype is associated with a gene
duplication.Up to 13 CYP2D6 copies could be the result
of this mutation.
6The extensive metabolizer phenotype
could therefore be a result of a homozygeous CYP2D6
wild-type genotype or a combination of alleles coding for
reduced or abundant activity (CYP2D6*3*4*5*6*10*17)
and alleles coding for increased activity.
In a study with haloperidol,which is degraded to reduced
haloperidol,a piperidine metobolite,and a presumably
neurotoxic substance haloperidol pyridinium (HPP
+)
(Figure 3), we noted that patients with the allele
CYP2D6*4,which exists in around 10% of the Caucasian
population and determines a slow metabolizer, show
higher plasma levels of haloperidol and reduced
haloperidol.At the same time,these patients showed a
poorer response to treatment and more side effects.
CYP3A4 is responsible for the increased occurrence of
the possibly neurotoxic metabolite HPP
+,
7,8 showing sim-
ilarities to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dinium (MPTP), which provoked symptoms similar to
Parkinson’s disease in heroin addicts.
9 This may also
cause undesired side effects, such as extrapyramidal
motor symptoms (EPS).
The new atypical antipsychotic risperidone is also metab-
olized by cytochrome CYP2D6. Patients who are
homozygous to the CYP2D6*4 allele,ie,slow metabolizers,
also show higher plasma levels. Furthermore, schizo-
phrenic patients who were heterozygous for cytochrome
CYP2C19 and CYP1A2 had fewer side effects.
Cytochrome CYP1A2*1F seems to be important too.
Using the PANSS (Positive and Negative Symptom
Scale),a poorer therapy response regarding the negative
symptoms could be seen in homozygous CYP1A2*1F
allele patients.
Pharmacokinetic aspects are also responsible for the
plasma levels of other drugs,eg,amisulpride.Tenfold dif-
ferences in the amisulpride plasma level can be measured
at the same dosage.We found the same results for the
atypical antipsychotic clozapine and also for other
antipsychotics,such as risperidone.Too low and too high
plasma levels reduce the therapy response and are the
reason for many side effects at high plasma levels.
Multidrug resistance protein
On the pharmacokinetic level,drug nonresponse can also
occur via mechanisms affecting the efflux of a diverse
range of drugs out of the cells or the permeability of the
blood–brain barrier. These mechanisms have evolved
during cell evolution in order to protect against toxic
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Table I. Reasons for nonresponse to treatment.
Different etiologies
Duration of untreated psychosis (DUP)
Pharmacokinetic aspects
• Poor metabolism
• Ultrarapid metabolism
• Drug–drug interactions
• Permeability of the blood–brain barrier
Variations in candidate genesenvironmental substances or metabolites. The extensively
described efflux mechanism is mediated via P-glycopro-
tein (P-gp) or MDR1. 
Multidrug resistance in humans is caused by the overex-
pression of the multidrug transporter: P-gp/MDR1. This
overexpression can be induced by drugs affecting the
MDR1 gene transcription or via functional genetic poly-
morphisms. 
P-gp is an adenosine triphosphate (ATP)–dependent
transmembrane efflux pump present in the hepatic, renal,
and endothelial cells forming the blood–brain barrier.
The only common structural feature of MDR1 substrate
compounds identified so far is their relatively hydropho-
bic and amphipathic nature. Risperidone and quetiapine
are relatively good substrates to the P-gp, whereas
haloperidol, clozapine, and flunitrazepam are hardly
transported or not at all.
10
So far, a total of 28 SNPs has been found on the MDR1
gene. Interestingly, the C2435T polymorphism, which
causes no amino acid change, has been found to be asso-
ciated with duodenal expression of MDR1.
11,12The C2435T
mutation is located in an noncoding promotor position
(exon 26) of the MDR1 gene
13 and is therefore unlikely to
be the only cause of this effect. Up to now, the results of
worldwide clinical studies are still inconsistent regarding
the association of the C2535T polymorphism with MDR1
expression, making further investigations necessary. 
N-Acetyltransferase
Acetylation by NAT is a phase II conjugation reaction. It
is controlled by two autosomal alleles at a single gene
locus. Around 60% of Caucasians are poor metabolizers,
whereas 20% of Orientals are slow metabolizers, and 90%
to 95% of Mongoloid races are fast acetylators. Three
NAT loci are found in humans: two expressed genes,
NAT1 and NAT2, and a pseudogene, N-acetyltransferase
pseudogene (NATP). NAT2 plays a role in the metabolism
of benzodiazepines, and theoretically also plays a role in
the metabolism of some antipsychotics.
Pharmacodynamic effects
The effect of both classical and atypical neuroleptics is
mainly due to a blockade of dopaminergic receptors in the
nigrostriatal and mesolimbic dopamine system. There are
five different dopamine receptors: D1 to D5. D1 and D5
stimulate adenylatecyclase, whereas D2, D3, and D4 inhibit
Pharmacological aspects
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Figure 3. Phase I metabolism of haloperidol. CPHP, chlorophenyhydroxypiperidine; CR, carbonylreductase; FBPS, fluorobutyrophenon acid; HPP
+, haloperi-
dol pyridinium; RHPP
+, reduced HPP
+. 
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14 Most important for the antipsychotic
effect is the inhibition of the D2 receptor,which is more or
less markedly caused by all antipsychotics.In comparison
to haloperidol,clozapine has a relatively higher effect on
the D4 receptor.
15 The O-substituted benzamide amisul-
pride has a relatively higher effect on the D3 receptor.
Moreover,other receptors,such as serotonin and norep-
inephrine, are inhibited and contribute as well to the
effect and side effects of antipsychotics. The different
genetic variants of the dopamine receptors seem to be
most important with regard to the responsiveness to ther-
apy.The D3 receptor exists in two different variations.
16
According to our findings,as well as those of others,atyp-
ical antipsychotics act much better with an allele with a
BAL1 polymorphism in exon I.Classical antipsychotics
such as haloperidol are less effective with this allele
(Figure 4). The effect of a single allele, however, only
partly contributes to the variance.Another study in 2000
by Arranz and Kerwin
17 has shown that the serotonin
5-HT2A receptor, the 5-HT2C receptor, the histamine
receptor type 2 H2R, and the serotonin transporter 
5-HTT2PR are additionally important.The combination
of the various polymorphisms made it possible to predict
the success of treatment with a rate of 77%, thus indi-
cating future possibilities in treatment.
18These findings
show that the interaction of various genetic variants
determines the effect of a drug and is thus responsible for
response or nonresponse.
Future aspects
The future of a medicinal treatment will be based on
individualized therapy.In addition to the heterogeneity
of diseases with different pathophysiologies,there is also
a difference in the effectiveness of drugs themselves due
to different genetic variants.Genetic alterations in cellu-
lar ion transporters,such as KCNE2,have impact on the
predisposition of patients to toxic effects of drugs.An
8T>A mutation in the KCNE2 gene can cause death by
a drug-induced long-QT syndrome.Since this mutation
occurs in 1.6% of the population, KCNE2 genotyping
should be considered in patients treated with antipsy-
chotics that are known to prolong the QT time intervals,
such as sertindole or ziprasisdone.
New microassay technologies will allow us to genotype
different candidate genes simultaneously,and to deter-
mine which are responsible for the pharmacodynamic
effects,as well to genotype different cytochromes,mak-
ing it possible to predict the plasma levels at the equiv-
alent dosage. Furthermore, the discovery of up to now
unknown genes affecting the action of a drug by means
of the so-called pharmacogenomics,ie,the recording of
the whole genome,will in the future become increasingly
important in both psychiatry and in other diseases.
Further factors that influence gene expression and pro-
tein production,measured by proteomics,will improve
our knowledge of drug effects. ❏
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Figure 4. Dopamine D3 receptor gene: BAL1 polymorphism in exon I and
response to treatment. Allele 2 of the BAL1 polymorphism is
associated with a better response to treatment in patients med-
icated with atypical antipsychotics. PANSS, Positive and Negative
Symptoms Scale; ANOVA, analysis of variance; P, PANSS posi-
tive; T, PANSS total.
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Variabilidad de la respuesta al tratamiento
antipsicótico en la esquizofrenia: aspectos
farmacogenéticos
La resistencia al tratamiento en la esquizofrenia se
mantiene como un problema de salud pública: alre-
dedor del 20% al 30% de los pacientes no respon-
den a la terapia con antipsicóticos. En alrededor de
un tercio de los pacientes se ha demostrado la efi-
cacia de la clozapina, pero los riesgos médicos y las
pruebas sanguíneas semanales limitan su aplicación
a gran escala. Además de considerar la heteroge-
neidad de la enfermedad y la duración de la 
psicosis no tratada, también son importantes los
aspectos farmacogenómicos. Las investigaciones
farmacogenómicas ofrecen la oportunidad de indi-
vidualizar la terapia antipsicótica de acuerdo con el
creciente conocimiento de la función y del efecto
del polimorfismo genético que afecta la farmacoci-
nética y la farmacodinámica de los antipsicóticos. A
nivel farmacocinético, las enzimas polimorfas que
participan en las fases I y II del metabolismo de los
medicamentos y las proteínas transportadoras influ-
yen en la concentración de los fármacos en las
estructuras blanco. Las enzimas del citoctromo P
450, la N-acetiltransferasa y la proteína de resis-
tencia a la acción de diversos medicamentos (“mul-
tidrug resistence protein-1”, MDR1) afectan parti-
cularmente este parámetro. Las alteraciones
genéticas que afectan las propiedades farmacodi-
námicas de los medicamentos tienen un impacto en
la evolución terapéutica que generalmente es inde-
pendiente de las dosis utilizadas. Un análisis com-
binado de los polimorfismos genéticos de los recep-
tores dopaminérgicos y serotoninérgicos de los
transportadores de neurotransmisores y de otras
estructuras blanco involucradas en los trastornos
psiquiátricos constituyen desde ya un poderoso
predictor de los resultados terapéuticos. A futuro,
la comprensión de otros factores que influyan en la
expresión génica y la producción de proteínas faci-
litará los tratamientos individualizados.
Variabilité de la réponse au traitement anti-
psychotique dans la schizophrénie : aspects
pharmacogénomiques
La résistance au traitement dans la schizophrénie
demeure un problème de santé publique : environ
20 % à 30 % de patients ne répondent pas au trai-
tement antipsychotique. La clozapine s’est montrée
efficace pour à peu près un tiers des patients mais
les risques médicaux et les contrôles sanguins heb-
domadaires limitent son application à grande
échelle. Si l’hétérogénéité de la maladie et la durée
de cette psychose non traitée sont importantes, les
aspects pharmacogénomiques doivent aussi être
considérés. Les recherches en pharmacogénomie
offrent l’opportunité d’individualiser les traite-
ments antipsychotiques d’après les connaissances
croissantes sur la fonction et les effets des 
polymorphismes génétiques qui influent sur la
pharmacocinétique et la pharmacodynamie des 
molécules antipsychotiques. Sur le plan pharmaco-
cinétique, les enzymes polymorphes qui intervien-
nent sur les phases I et II du métabolisme des médi-
caments et les protéines de transport influent sur la
concentration des médicaments au niveau de la
structure cible. Les enzymes cytochrome P450, la N-
acétyltransférase et la protéine de résistance à l’ac-
tion de plusieurs médicaments (« multidrug resis-
tance protein–1 », MDR1) jouent particulièrement
sur ce paramètre. Les altérations génétiques agis-
sant sur les propriétés pharmacodynamiques des
médicaments ont un impact sur les résultats théra-
peutiques généralement indépendant du schéma
posologique. L’analyse combinée des polymor-
phismes génétiques des récepteurs dopaminer-
giques et sérotoninergiques, des transporteurs des
neurotransmetteurs et d’autres structures cibles
impliquées dans les troubles psychiatriques consti-
tue déjà un prédicteur puissant des résultats théra-
peutiques. Comprendre comment d’autres facteurs
influent sur l’expression des gènes et la production
des protéines facilitera les traitements individuali-
sés dans l’avenir.Pharmacogenomic aspects of response to antipsychotic therapy - Ackenheil and Weber  Dialogues in Clinical Neuroscience - Vol 6 . No.1 . 2004
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